PUBLIC COMPANY
saveJohnson & Johnson Innovative Medicine
updated 15d ago
community read0 votes
pipeline
11
marketed
9
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(11)
pipeline depth11 products
1Phase 21Phase 39Marketed
Marketed
(canagliflozin + metformin hydrochloride ER)
Type 2 Diabetes
Marketed(canagliflozin + metformin hydrochloride)
Type 2 Diabetes
MarketedCANAGLIFLOZIN
Type 2 Diabetes
MarketedInvega Hafyera
Schizophrenia
MarketedXarelto
Atrial Fibrillation
Marketedesketamine hydrochloride
Major Depressive Disorder
Marketedpaliperidone palmitate ER
Schizophrenia
Marketedpaliperidone palmitate LA
Schizoaffective Disorder
Marketedrisperidone PR
Bipolar Disorder (Manic Depression)
Phase 3botaretigene sparoparvovec
Retinitis Pigmentosa (Retinitis)
Phase 2JNJ-2056
Alzheimer's Disease
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Jennifer Taubert announces retirement from J&J; Takeda's global TYK2 leader exits→ One of the most influential pharma execs at Johnson & Johnson is retiring. Jennifer Taubert, the worldwide chair of Johnson & Johnson Innovative Medicine, will hand the reins to Tom ...endpoints · 8d ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that